Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push
Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to expand development of treatments for rare blood cancers known as myeloproliferative neoplasms, its 14th or 15th acquisition of 2026.
·3 sources